Edwardo Ramos Cortes, MD
Physical Medicine & Rehabilitation · San Juan, PRNPI 1831152677
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $184,980 of the $247,008 with a category attached, or 74.9%. 15 manufacturers reported payments, led by Biogen at 47.2% of the total. Reporting peaked in 2022 at $54,272 and has fallen 53.9% since, to $25,020 in 2025. Among physical medicine & rehabilitation clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 346 payments — averaging $713.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$117K
- Genentech USA, Inc.$53K
- AbbVie$49K
- PTC Therapeutics, Inc.$10K
- Sarepta Therapeutics, Inc.$10K
- Medtronic$4K
- plus $4K from 9 others
Across 93 payments — averaging $1597.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Pharma SAS$110K
- Catalyst Pharmaceuticals, Inc.$34K
- Genentech, Inc.$4K
- PTC Therapeutics, Inc.$301
What the payments were for
- Consulting fees$37,25215%
- Speaking & faculty fees$184,98075%
- Travel & lodging$15,4046%
- Food & beverage$9,3454%
- Education$280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 126 | $116,666 |
| Genentech USA, Inc. | 55 | $53,249 |
| AbbVie(2 entities) | 44 | $49,098 |
| PTC Therapeutics, Inc. | 48 | $9,772 |
| Sarepta Therapeutics, Inc. | 11 | $9,718 |
| Medtronic(2 entities) | 5 | $4,474 |
| Genentech, Inc. | 9 | $1,922 |
| NS Pharma, Inc. | 32 | $1,162 |
| Catalyst Pharmaceuticals, Inc. | 7 | $447 |
| Ipsen Biopharmaceuticals, Inc | 2 | $163 |
| Johnson & Johnson | 3 | $145 |
| Sanofi | 1 | $115 |
| Tanabe Pharma America, Inc. | 1 | $48 |
| Novartis | 1 | $20 |
| PBG Puerto Rico LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$247,008 in reported general payments places this provider in the 95th percentile of 156 physical medicine & rehabilitation providers in Puerto Rico.
See all physical medicine & rehabilitation providers in Puerto Rico →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvrysdiRisdiplam | 45 | $1,208,980 |
| BotoxOnabotulinumtoxina | 18 | $25,770 |
| EliquisApixaban | 30 | $14,998 |
| TradjentaLinagliptin | 12 | $6,315 |
| Gabapentin | 125 | $1,458 |
| Baclofen | 64 | $883 |
| LantusInsulin Glargine,hum.Rec.Anlog | 12 | $786 |
| Losartan Potassium | 62 | $520 |
| Pantoprazole Sodium | 19 | $510 |
| Atorvastatin Calcium | 55 | $425 |
| Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen | 36 | $395 |
| Nifedipine ErNifedipine | 15 | $340 |
| Insulin Lispro | 13 | $337 |
| Clonazepam | 19 | $328 |
| Levothyroxine Sodium | 28 | $285 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Evrysdi | $53,249 | $1,208,98045 claims |
| AbbVieBotox | $49,098 | $25,77018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 156 physical medicine & rehabilitation providers in Puerto Rico.
Other physical medicine & rehabilitation in San Juan
- Rafael VaquerSan Juan$2K
- Melissa Alvarez PerezSan Juan$2K
- Victor Rosado TorresSan Juan$1K
- Veronica Rodriguez de la CruzSan Juan$1K
- Miguel Arroyo-RamosSan Juan$788
- Kevin de Jesus-MoralesSan Juan$644
- Miguel Cardona CancioSan Juan$528
- Eduardo Maldonado-ColonSan Juan$467
- Anthony Lombardi GonzalezSan Juan$411
- Felix Perez MorciglioSan Juan$345
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.